Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 7/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.44 |
| ▸ | CCNK | O75909 | 12/20 | 0.44 |
| ▸ | CDK9 | P50750 | 12/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 12/20 | 0.44 |
| ▸ | CDK2 | P24941 | 11/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.44 |
| ▸ | CCNH | P51946 | 5/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19605656 | 0.93 | CCNK (0.48) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19600383 | 0.92 | CCNT1 (0.43) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19600367 | 0.92 | CDK7 (0.49) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19605708 | 0.85 | CCNK (0.47) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL17688431 | 0.84 | CCNT1 (0.58) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19600378 | 0.83 | CDK7 (0.47) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL17688397 | 0.83 | CCNK (0.54) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19600376 | 0.79 | CCNK (0.42) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL19600381 | 0.78 | CCNK (0.47) | CDK7CCNT1CCNKCDK9CDK12 | |
| SCHEMBL17688384 | 0.77 | CCNT1 (0.57) | CDK7CCNT1CCNKCDK9CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNT1 33/4885CCNK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.